Laser in wounds: knowledge translation to an effective and innovative nursing practice / Láser em heridas: translación del conocimiento para uma práctica efectiva e inovadora en enfermería / Laser em feridas: translação do conhecimento para uma prática efetiva e inovadora na enfermagem

ABSTRACT Objective To describe the knowledge translation obtained through research of low-level laser therapy to wound treatment in the clinical practice. Methods Experience report about implementation strategies of this new technology in a university hospital, being an extension course the main one, developed between May and December 2019. Results The course was carried out by researchers in partnership with clinical nurses to 13 nurses from different areas with previous experience in wound care. Were taught 30 theoretical-practical class hours, part of them supervised in a real clinical setting, besides case studies. From that, an exclusive nursing consultation schedule of laser therapy was created at the outpatient and its use was also improved to patients admitted in several units of the hospital. Final considerations The knowledge translation developed about laser therapy allowed its implementation as a technology in wound treatment, qualifying the professional practice and benefiting the treatment of patients with wounds.

RESUMEN Objetivo Describir la traslación del conocimiento obtenido en investigación de la terapia con láser de baja potencia para el tratamiento de heridas en la práctica clínica. Métodos Relato de experiencia sobre estrategias para la implementación de esta nueva tecnología en un hospital universitario, con un curso de extensión desarrollado entre mayo y diciembre/2019. Resultados El curso fue realizado por investigadores en alianza con enfermeras especializadas para 13 enfermeros de diferentes áreas y experiencias en el cuidado con heridas. Fueran dados 30 horas de clases teórico-prácticas supervisadas en un entorno clínico real y estudios de casos. En consecuencia de esto, se creó consultas de enfermería de terapia láser, así como un aumento de esta terapia para los pacientes hospitalizados. Consideraciones finales La transferencia de conocimiento sobre la terapia con láser permitió la implantación de esta tecnología en el tratamiento de heridas, con práctica profesional calificada y beneficio el tratamiento de pacientes con heridas.

RESUMO Objetivo Descrever a translação do conhecimento obtido em pesquisa sobre terapia a laser de baixa potência para o tratamento de feridas na prática clínica. Métodos Relato de experiência sobre estratégias de implementação dessa nova tecnologia em um hospital universitário, sendo um curso de extensão a principal delas, desenvolvido entre maio e dezembro/2019. Resultados O curso foi realizado por pesquisadores em parceria com enfermeiros assistenciais para 13 enfermeiros de diferentes áreas e experiências no cuidado a pacientes com feridas. Foram ministradas 30 horas de aulas teórico-práticas, parte das mesmas supervisionadas em cenário clínico real, além de estudos de caso. A partir disso, foi criada uma agenda de consulta de enfermagem de laserterapia no ambulatório, bem como incrementado essa terapia em pacientes hospitalizados. Considerações finais A translação do conhecimento sobre laserterapia permitiu a implantação dessa tecnologia no tratamento de feridas, qualificando a prática profissional e beneficiando o tratamento de pacientes com feridas.

AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease.

We previously developed orthosteric M1 muscarinic agonists (e.g. AF102B, AF267B and AF292), which act as cognitive enhancers and potential disease modifiers. We now report on a novel compound, AF710B, a highly potent and selective allosteric M1 muscarinic and σ1 receptor agonist. AF710B exhibits an allosteric agonistic profile on the M1 muscarinic receptor; very low concentrations of AF710B significantly potentiated the binding and efficacy of carbachol on M1 receptors and their downstream effects (p-ERK1/2, p-CREB). AF710B (1-30 µg/kg, p.o.) was a potent and safe cognitive enhancer in rats treated with the M1 antagonist trihexyphenidyl (passive avoidance impairment). These effects of AF710B involve σ1 receptor activation. In agreement with its antiamnesic properties, AF710B (at 30 nM), via activation of M1 and a possible involvement of σ1 receptors, rescued mushroom synapse loss in PS1-KI and APP-KI neuronal cultures, while AF267B (1 µM) was less potent in PS1-KI and ineffective in APP-KI models, respectively. In female 3xTg-AD mice, AF710B (10 µg/kg, i.p./daily/2 months) (i) mitigated cognitive impairments in the Morris water maze; (ii) decreased BACE1, GSK3ß activity, p25/CDK5, neuroinflammation, soluble and insoluble Aß40, Aß42, plaques and tau pathologies. AF710B differs from conventional σ1 and M1 muscarinic (orthosteric, allosteric or bitopic) agonists. These results highlight AF710B as a potential treatment for Alzheimer's disease (e.g. improving cognitive deficits, synaptic loss, amyloid and tau pathologies, and neuroinflammation) with a superior profile over a plethora of other therapeutic strategies.

Surface degradation of lithium disilicate ceramic after immersion in acid and fluoride solutions.

PURPOSE: To analyze whether immersion in sodium fluoride (NaF) solutions and/or common acidic beverages (test solutions) would affect the surface roughness or topography of lithium disilicate ceramic. METHODS: 220 ceramic discs were divided into four groups, each of which was subdivided into five subgroups (n = 11). Control group discs were immersed in one of four test beverages for 4 hours daily or in artificial saliva for 21 days. Discs in the experimental groups were continuously immersed in 0.05% NaF, 0.2% NaF, or 1.23% acidulated phosphate fluoride (APF) gel for 12, 73, and 48 hours, respectively, followed by immersion in one of the four test beverages or artificial saliva. Vickers microhardness, surface roughness, scanning electron microscopy (SEM) associated with energy dispersive spectroscopy, and atomic force microscopy (AFM) assessments were made. Data were analyzed by nested analysis of variance (ANOVA) and Tukey's test (α = 0.05). RESULTS: Immersion in the test solutions diminished the microhardness and increased the surface roughness of the discs. The test beverages promoted a significant reduction in the Vickers microhardness in the 0.05% and 0.2% NaF groups. The highest surface roughness results were observed in the 0.2% NaF and 1.23% APF groups, with similar findings by SEM and AFM. Acidic beverages affected the surface topography of lithium disilicate ceramic. Fluoride treatments may render the ceramic surface more susceptible to the chelating effect of acidic solutions.

Alzheimer-associated Aß oligomers impact the central nervous system to induce peripheral metabolic deregulation.

Alzheimer's disease (AD) is associated with peripheral metabolic disorders. Clinical/epidemiological data indicate increased risk of diabetes in AD patients. Here, we show that intracerebroventricular infusion of AD-associated Aß oligomers (AßOs) in mice triggered peripheral glucose intolerance, a phenomenon further verified in two transgenic mouse models of AD. Systemically injected AßOs failed to induce glucose intolerance, suggesting AßOs target brain regions involved in peripheral metabolic control. Accordingly, we show that AßOs affected hypothalamic neurons in culture, inducing eukaryotic translation initiation factor 2α phosphorylation (eIF2α-P). AßOs further induced eIF2α-P and activated pro-inflammatory IKKß/NF-κB signaling in the hypothalamus of mice and macaques. AßOs failed to trigger peripheral glucose intolerance in tumor necrosis factor-α (TNF-α) receptor 1 knockout mice. Pharmacological inhibition of brain inflammation and endoplasmic reticulum stress prevented glucose intolerance in mice, indicating that AßOs act via a central route to affect peripheral glucose homeostasis. While the hypothalamus has been largely ignored in the AD field, our findings indicate that AßOs affect this brain region and reveal novel shared molecular mechanisms between hypothalamic dysfunction in metabolic disorders and AD.

Anti-inflammatory effects of compounds alpha-humulene and (-)-trans-caryophyllene isolated from the essential oil of Cordia verbenacea.

This study evaluated the anti-inflammatory properties of two sesquiterpenes isolated from Cordia verbenacea's essential oil, alpha-humulene and (-)-trans-caryophyllene. Our results revealed that oral treatment with both compounds displayed marked inhibitory effects in different inflammatory experimental models in mice and rats. alpha-humulene and (-)-trans-caryophyllene were effective in reducing platelet activating factor-, bradykinin- and ovoalbumin-induced mouse paw oedema, while only alpha-humulene was able to diminish the oedema formation caused by histamine injection. Also, both compounds had important inhibitory effects on the mouse and rat carrageenan-induced paw oedema. Systemic treatment with alpha-humulene largely prevented both tumor necrosis factor-alpha (TNFalpha) and interleukin-1beta (IL-1beta) generation in carrageenan-injected rats, whereas (-)-trans-caryophyllene diminished only TNFalpha release. Furthermore, both compounds reduced the production of prostaglandin E(2) (PGE(2)), as well as inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) expression, induced by the intraplantar injection of carrageenan in rats. The anti-inflammatory effects of alpha-humulene and (-)-trans-caryophyllene were comparable to those observed in dexamethasone-treated animals, used as positive control drug. All these findings indicate that alpha-humulene and (-)-trans-caryophyllene, derived from the essential oil of C. verbenacea, might represent important tools for the management and/or treatment of inflammatory diseases.

The effects of diacerhein on mechanical allodynia in inflammatory and neuropathic models of nociception in mice.

In this study we analyzed the systemic antiallodynic properties of diacerhein, a drug used to treat osteoarthritis, in inflammatory and neuropathic models of nociception in mice. The effects of diacerhein were compared with those of gabapentin, a drug used clinically for the management of neuropathic pain. Similar to gabapentin, diacerhein was able to significantly reverse the mechanical allodynia induced by carrageenan. A significant inhibition of carrageenan-induced nociception was also observed when diacerhein was administered by the intrathecal but not by the intraplantar route. The treatment with diacerhein or with gabapentin also inhibited the mechanical allodynia induced by complete Freund's adjuvant (CFA) or after the partial ligation of the sciatic nerve (PLSN). In the same range of doses, diacerhein or gabapentin did not affect the locomotor activity, motor coordination, or body temperature of the animals. The present results indicate that diacerhein produces marked antiallodynic effects in carrageenan and CFA nociception models and also inhibits the neuropathic pain after PLSN, with an efficacy similar to that observed for gabapentin. Diacerhein may be a potentially interesting tool for the management of inflammatory and neuropathic pain.